Applied DNA Sciences Stock (NASDAQ: APDN)

Applied DNA Sciences (NASDAQ:APDN) Stock, Quote.Headers.trade-ideas

Applied DNA Sciences

Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.

vaccine-4892048

News

APDN

Applied DNA Sciences has expanded its mpox testing services. Shares rose 37% after the announcement.

Why Applied DNA Sciences (APDN) Stock Is Skyrocketing

movers image

Intraday Update

Markets

Movers

AAOI

AGMH

AIXI

AMAT

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MNOV

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

wall-street-ai17

Broad U.S. Equity ETFs

Exclusives

Tech

Trading Ideas

ETFs

AAPL

AMZN

ASTS

CING

CRWD

GOVX

INDO

LUMN

LUNR

NVDA

PLTR

SERV

SMCI

TSLA

VRAX

ZAPP

A look at the top 20 most-searched tickers on Benzinga Pro for the month of August.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences Inc

<a href="https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.">https://www.ema.europa.eu/en/news/ema-recommends-extending-indication-mpox-vaccine-adolescents#:~:text=EMA%20has%20recommended%20extending%20the,the%20vaccinia%20virus%20in%20adults.</a>
&nbsp;
EMA has recommended extending the indication of the smallpox and mpox vaccine <a href="https://www.ema.europa.eu/node/65501">Imvanex</a> to adolescents from 12 to 17 years of age.
Imvanex is already authorised in the European Union (EU) to protect against smallpox, mpox and the disease caused by the vaccinia virus in adults. It contains a live, highly weakened form of a virus called "modified vaccinia virus Ankara" (MVA-BN), which is related to the smallpox virus. EMA's human medicines committee (CHMP) based the recommendation to extend the use of Imvanex to adolescents on the <a href="https://www.clinicaltrials.gov/study/NCT05740982">interim results of a study</a> that compared the vaccine's ability to generate an immune response (produce virus-specific antibodies) in 315 adolescents and in 211 adults.
The immune response in adolescents was similar to adults. Therefore, it is inferred that the vaccine will provide similar protection in adolescents to that expected in adults. According to the submitted data, the safety profile of Imvanex in adolescents was comparable to that seen in adults and no additional risk has been identified. As part of its recommendation, EMA has requested the marketing authorisation holder to submit the final results of the study by 30 May 2025 to further characterise the information about safety in adolescents.
The Agency's assessment has important implications for the global response to the mpox outbreak in the Democratic Republic of the Congo (DRC) and other countries, which was <a href="https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern">declared a public health emergency of international concern (PHEIC)</a> by the World Health Organization (WHO) on 14 August 2024.
EMA is the regulatory agency of record for <a href="https://www.who.int/news/item/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox">prequalification of this vaccine by WHO</a> on 13 September 2024. This means that CHMP's assessment constitutes the basis for WHO prequalification approval to facilitate timely and increased access to this vaccine in communities with urgent need. Previously, EMA's assessment was also taken into account by the national regulatory authority of the DRC in the fast-track approval of the vaccine. In addition, WHO has cooperated in EMA's assessment of the extension of indication in adolescents, a population that is particularly vulnerable to mpox.
Mpox is a disease that is transmitted to people by animals, mainly rodents, but can also spread between people with direct contact. It is endemic in certain parts of Central and West Africa. The current surge in cases in the DRC and several neighbouring countries is driven by the mpox clade I strain that is known to cause a more severe form of mpox in humans than the mpox clade II strain that spread during the 2022/2023 PHEIC. Mpox can be fatal for people with weak immune systems.
Data indicate that Imvanex protects against both the clade I and clade II mpox strains.
In the EU, decisions on how vaccinations should be given are the prerogative of the expert bodies guiding vaccination campaigns in each Member State. The European Centre for Disease Prevention and Control (ECDC) <a href="https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024">published advice for public health authorities for mpox</a> on their website.

Biotech

Global

General

AEMD

CMRX

MRNA

TNXP

'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA

Applied DNA Regains Compliance With Nasdaq Minimum Bid Price Requirement

- Co-Hosts Seminar with mRNA CDMO Kudo Bio to Demonstrate Linea IVT Capability for Rapid mRNA Manufacturing -
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / <a href="https://pr.report/2ok4">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) (Applied DNA), a leader in PCR-based DNA technologies, today announced its participation at upcoming mRNA events in Boston this week:
<a href="https://pr.report/2ok5">3rd Annual mRNA Process Development &amp; Manufacturing Summit</a> - members of Applied DNA's Biotherapeutics Sales and Business Development teams (collectively 'LineaRx,' a majority-owned Applied DNA company) will attend the 3rd Annual mRNA Process Development &amp; Manufacturing Summit taking place September 17-19, 2024.
LineaRx will present its Linea&#x2122; IVT platform - a combination of an enzymatically produced DNA template (Linea&#x2122; DNA IVT template) coupled with a next-generation RNA polymerase (Linea&#x2122; RNAP) - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
<a href="https://pr.report/2ok6">Lunch/Learn</a> with <a href="https://pr.report/2ok7">Kudo Biotechnology</a> - LineaRx and mRNA CDMO partner Kudo Biotechnology will co-host a seminar luncheon to present data from a proof-of-concept study and a case study to demonstrate how Linea IVT can support rapid manufacturing of dsRNA-mitigated mRNA. The Lunch/Learn will be held on Thursday, September 19, from 11:00 a.m. - 2:00 p.m. ET at <a href="https://pr.report/2ok8">MassBio</a> and will be webcast-accessible <a href="https://pr.report/2ok9">here</a>.

Events

Applied DNA To Showcase Linea IVT As A High-Yield, dsRNA-Mitigated Platform For the GMP Manufacture Of RNA At The 3rd Annual mRNA Process Development & Manufacturing Summit September 17-19, 2024

- Recurring and Accelerated Receipt of Order Reflects Customer Commitment to Linea DNA -
STONY BROOK, NY / ACCESSWIRE / September 17, 2024 / <a href="https://pr.report/2n6a">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced it has received a follow-on order valued at more than $500,000 for a quantity of Linea&#x2122; DNA from a global manufacturer of in vitro diagnostics (IVDs). The follow-on order was placed under a long-standing supply agreement for the bulk manufacture of Linea DNA (non-therapeutic) used in the manufacture of a cancer diagnostic test. Applied DNA expects to deliver on the order over four quarterly shipments in calendar 2025.

Contracts

Reported Earlier, Applied DNA Receives Linea DNA Follow-On Order Valued At More Then $500K From Global Manufacturer Of IVDs For Cancer Diagnostic Application

US To Stay Committed In Bringing Mpox Outbreak Under Control

Morocco Records First Case Of Mpox

Applied DNA Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>), through its subsidiary Applied DNA Clinical Labs (ADCL), has expanded its clinical testing services for mpox (formerly known as monkeypox). Shares rose some 37% to $1.76 Wednesday morning following a <a href="https://www.benzinga.com/pressreleases/24/09/ac40813623/applied-dna-launches-mpox-clade-i-and-clade-ii-testing-service">press release</a> from the company. Applied DNA Sciences says the new service includes detection of both Mpox Clade I and Clade II, following approval from regulatory bodies like the New York State Department of Health and the FDA. 
Applied DNA Sciences also says this move aims to help New York and other states combat the rising Mpox threat by enhancing access to testing. ADCL&#8217;s Linea Mpox Virus 1.0 Assay, initially approved in 2022 for detecting Clade II, was recently validated to detect Clade I as well. Testing will be conducted at ADCL's lab in Stony Brook, NY.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40812986/inflation-slows-to-2-5-in-august-lowest-rate-since-february-2021-core-index-remai">Historic Inflation Data Hits Lowest Level Since February 2021 — But One Segment Remains Stubbornly High</a>
<h2 class="wp-block-heading">How To Buy APDN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Applied DNA Sciences&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, APDN has a 52-week high of $28.40 and a 52-week low of $0.31.

WIIM

Applied DNA Sciences shares are trading higher after the company announced it launched the Mpox Clade I and Clade II testing service.

<a href="https://pr.report/2gpx">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) (Applied DNA), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has launched an expansion of its clinical testing services for the detection of Mpox (formerly monkeypox) to include testing for both mpox Clade I and Clade II. The launch of the expanded mpox testing service comes after ADCL's interaction with relevant regulatory bodies, including the New York State Department of Health (NYSDOH) and the U.S. Food and Drug Administration (FDA).

Applied DNA Launches Mpox Clade I And Clade II Testing Service

Applied DNA Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NYSE">APDN</a>) short percent of float has risen 142.36% since its last report. The company recently reported that it has 1.73 million shares sold short, which is 16.82% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Applied DNA Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725986715_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Applied DNA Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Applied DNA Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Applied DNA Sciences's peer group average for short interest as a percentage of float is 4.20%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Applied DNA Sciences's Recent Short Interest

Macro Economic Events

Economics

CDC Says There Have Been No Reported Cases Of Clade I Mpox In The U.S. As Of September 6; In The U.S., Clade II Mpox Is Still Circulating At Low Levels

<a href="https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926">https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926</a>
&nbsp;
Senior Biden administration officials said Friday that the United States is preparing for the possible arrival of <a href="https://www.nbcnews.com/health/health-news/mpox-strain-spreads-cdc-who-stronger-warnings-rcna165155">a more severe version of mpox</a>, which has taken off in the Democratic Republic of Congo and other countries in Africa resulting in more than 600 deaths there.
As of Thursday, there have been more than 24,800 reported cases of this version of the virus, <a href="https://www.nbcnews.com/health/health-news/mpox-virus-outbreak-symptoms-2024-spread-rcna166778">known as clade 1</a>, so far this year, the World Health Organization said at a separate briefing Friday.&nbsp;The WHO declared the outbreak a<a href="https://www.nbcnews.com/health/health-news/who-declares-mpox-global-public-health-emergency-second-time-rcna166601"> global health emergency</a> in August.
Last month,<a href="https://www.nbcnews.com/health/health-news/sweden-confirms-first-case-mpox-strain-congo-rcna166763"> Sweden confirmed a case of clade 1</a>, the first known case outside of Africa, followed by a case in Thailand several days later. Both patients had spent time in Africa.
A different version of mpox, clade 2, triggered a global outbreak in 2022 and a surge of cases in the U.S. Clade 1 is more severe and can kill up to 10% of people infected, though recent death rates have been around 1% to 3.3%, <a href="https://www.cdc.gov/poxvirus/mpox/about/index.html">according to the CDC.</a>
On a call with reporters, senior administration officials said that as infections have risen in Africa, the U.S. has been gearing up for its own cases.&nbsp;
"We've been preparing for the arrival of clade 1 in the United States for many months now, especially as we saw the outbreak in DRC and neighboring countries accelerate," one official said.
The government is expanding its mpox surveillance efforts, primarily through wastewater analysis, and is reaching out to the medical community to educate members on what to watch for, including the severity of clade 1 and how it spreads, according to officials.
Officials said they're also making sure testing is more widely available.
Any doctor in the U.S. can order an mpox test that can be run through a national laboratory. If positive, it can be tested for clade 2. If those results are negative for clade 2, the doctor can make a presumptive diagnosis of clade 1; that diagnosis will need to be officially confirmed by the Centers for Disease Control and Prevention, according to officials.
The Jynneos mpox vaccine, given in two doses, is effective against both clade 1 and clade 2 of mpox.
The CDC's vaccine recommendation remains limited to anyone who is considered at high risk of catching the virus, mainly gay and bisexual men.&nbsp;
Most people with health insurance can get the vaccine at major pharmacy retail chains including CVS and Walgreens, the officials said. The vaccine is also available for free at public health departments and community health centers.
More vaccines are being held in the U.S. national stockpile, officials said, although they declined to say how many.&nbsp;
"There is a sufficient amount of vaccine for the U.S. population," an official said.&nbsp;
The U.S. is also working with government scientists and drug companies to develop potential new treatments. There are currently no approved treatments for mpox. The Food and Drug Administration has approved an antiviral treatment known as TPOXX for smallpox, which is closely related to mpox, although a recent clinical trial found that the drug is <a href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo">not effective against clade 1</a>.&nbsp;

'U.S. Prepares For Possible Arrival Of More Severe Strain Of Mpox; There Have Been Nearly 25,000 Cases Of The Clade 1 Version Of Mpox In Africa So Far This Year" - NBC

<a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523">https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523</a>
&nbsp;
Today, close to 100,000 mpox vaccine doses will arrive in the Democratic Republic of Congo (DRC), making these the first delivery of the vaccine to the country. A second delivery amounting to around 100,000 vaccines is expected to arrive in the coming days.
These vaccines are part of the 215,000 MVA-BN&#xAE; <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4244">vaccine doses</a> that the European Commission's Health Emergency Preparedness and Response Authority (HERA) procured and pledged to share to affected countries in Africa as an immediate response to the mpox outbreak.
Via Team Europe, an additional 351,500 of doses from France, Germany, Spain, Malta, Portugal, Luxembourg, Croatia, Austria, Poland, and potentially some other Member States, will be donated to the Africa CDC to distribute to affected countries. This brings the total number of vaccine doses donated from Team Europe to at least 566,500, which includes the above 215,000 doses that were donated by HERA in cooperation with the Bavarian Nordic pharmaceutical company.
EU support for the mpox outbreak
This initiative is part of a comprehensive set of EU actions put in place as part of the EU Global Health Strategy, which represents the external dimension of a strong European Health Union and is a key component of Global Gateway, to support partners in the rest of the world.
The Commission is actively coordinating the response of EU Member States to the mpox outbreak via regular meetings of the HERA Board and the Health Security Committee, which allows prompt coordination when dealing with health threats.
The Emergency Response Coordination Centre (ERCC) is in contact with EU Member States given that, if activated, the EU Civil Protection Mechanism (rescEU) can be used to channel mpox vaccines and therapeutics to countries in need. Specialised expertise, medical items and equipment could also be deployed based on these needs.
Under the Global Gateway investment strategy, the Commission is committed to advancing public health in Africa. The Commission has focused on strengthening health systems, securing pharmaceutical supply chains, and developing local manufacturing through investment in infrastructure and a supportive regulatory environment. An example of this is the Team Europe Initiative on manufacturing and access to vaccines, medicines and health technologies (Mav+) and on Sustainable Health Security.
The European Centre for Disease Prevention and Control (ECDC) is supporting epidemiological work on the ground in the DRC, working with the Africa CDC to identify priority areas for mpox research, and is leading coordination of the Network of Major CDCs globally. HERA is also working with the Africa CDC with the aim of expanding access to mpox diagnostics and sequencing in the region, with a €9.4 million grant foreseen for early autumn.
The Commission has released €1 million in humanitarian aid to support care, prevention, epidemiological surveillance, risk communication and distribution of kits in the eastern DRC as well as €200,000 in Burundi to assist the Burundi Red Cross in preparing for and responding to the epidemic. Under the European Humanitarian Response Capacity (EHRC), in cooperation with the ECDC, two epidemiologists were deployed on 4 September to the DRC. In addition, the Commission provides regular humanitarian funding for surveillance programmes, including in Uganda and Kenya's camps and settlements and expertise to assist in the response.

'First Delivery Of Mpox Vaccine Doses From The Commission Arrive Today In The Democratic Republic Of Congo' - European Commission

Applied DNA Sciences shares are trading lower. The company announced it received a subcontract award from LRQA for a pilot isotopic testing program.

- Pilot Project To Demonstrate Effectiveness of CertainT&#xAE; for Cotton Textile Traceability -
STONY BROOK, NY / ACCESSWIRE / September 4, 2024 / <a href="https://pr.report/28l1">Applied DNA Sciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) (Applied DNA), a leader in PCR-based DNA technologies, today announced the receipt of a subcontract award from <a href="https://pr.report/28l2">LRQA</a> following a competitive tender for a pilot isotopic testing program. Under the terms of the subcontract, Applied DNA, together with its traceability partner, Isotech (a Stratum Reservoir company), will employ CertainT&#xAE; to conduct isotopic testing and analysis to support cotton traceability in Pakistan. Financial terms of the subcontract were not disclosed.
<a href="https://pr.report/28l3">CertainT</a> is Applied DNA's textiles traceability platform that uses forensic, multiple-proof-point evidence to enable source and authenticity verification of materials and products at any point as they are transformed through global supply chains. LRQA is a leading global assurance company that brings together decades of unrivaled expertise in assessment, advisory, inspection, and cybersecurity services.
The subcontract with Applied DNA was issued in support of the <a href="https://pr.report/28l4">Global Trace Protocol project</a> (the "Project"), a U.S. Department of Labor-funded initiative implemented by LRQA (known as ELEVATE during the Project's inception) that is designed to reduce child and forced labor in global supply chains through traceability. The Project engages with trace experts, global brands, Pakistan's cotton sector, and worker organizations to design, implement, and assess the pilot trace tool to improve its future application and develop publicly available commodity-agnostic trace resources for enhanced due diligence.

Applied DNA Selected By LRQA For Isotopic Testing Pilot Project In Pakistan; Financial Terms Of The Subcontract Were Not Disclosed

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).
Nikola shares dipped 10.4% to $7.28 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares jumped 103% to $0.6719. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 85% to $3.70.</li>
<li>SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) surged 65% to $2.3950 after the company announced it entered into a definitive agreement to be acquired by Highwire Capital for $2.50 per share.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) rose 62.7% to $2.31.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares jumped 56% to $1.0250 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) gained 44.6% to $1.25 after the company announced it recently launched both Apple CarPlay and Android Auto interfaces for its faidr mobile application.</li>
<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) surged 43.5% to $115.92 after the company announced it selected VAX-31 to advance to an adult Phase 3 program following topline results from its Phase 1/2 study.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 28.8% to $21.69.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 21.8% to $6.57 after the company received a favorable legal ruling from the U.S. ITC in its patent infringement complaint against Voltage, LLC and a related foreign entity.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) jumped 17.5% to $6.55 after the company announced it dosed 5 new patients in its ACHIEVE Phase 2b trial.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) rose 16.5% to $1.27.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 16% to $1.4150 after the company appointed former Stellantis executive Jean-Francois Mady as its new CFO.</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) surged 15.8% to $2.34.</li>
<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) gained 15.3% to $1.73. MediciNova recently announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 for post-COVID conditions.</li>
<li>GD Culture Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) rose 12.8% to $6.86.</li>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) jumped 12.6% to $5.99.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) gained 11.4% to $8.29.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) rose 11.3% to $1.3250.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) gained 10.7% to $12.57 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 9.4% to $17.91 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
<li>Intchains Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) climbed 8.1% to $7.89.</li>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) gained 8.1% to $49.04 after the company announced an update on enrollment in the Phase 2 TROPOS trial.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 4.5% to $12.94. Friday, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares dipped 42.2% to $4.68.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) fell 31.7% to $31.47. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 31.3% to $1.75 after jumping 60% on Friday.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) dipped 29.3% to $1.06 after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) fell 25.8% to $1.1499. Brenmiller recently reported a year-over-year increase in H1 EPS results. Also, the company announced a projected pipeline valued up to $500 million.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) dipped 22.8% to $1.13.</li>
<li>Four Seasons Education (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEDU#NYSE">FEDU</a>) fell 21.8% to $13.30.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) declined 21.6% to $3.55.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 18.8% to $1.5506.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) dipped 18.6% to $3.99.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 16.1% to $8.49.</li>
<li>LightInTheBox Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NASDAQ">LITB</a>) declined 14.3% to $0.4455.</li>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) fell 12.7% to $16.97 as the company announced planned CEO transition.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) fell 10.8% to $4.2350.</li>
<li>Nova Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) declined 9.6% to $202.16.</li>
<li>Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) fell 8.5% to $81.15.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) fell 8.5% to $109.35.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 8.3% to $159.27 ahead of the September 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) dipped 8% to $75.43.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) fell 7.2% to $70.73.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) declined 7% to $20.52.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 6.2% to $185.01.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent080124&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for the month of August 2024. Current prices and year-to-date performance are based on Aug. 30 and do not include dividends. April search results were not tracked.
1. NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>Current Price: $119.37</li>
<li>52-Week Range: $39.23 to $140.76</li>
<li>Year-to-Date Return: +147.8%</li>
<li><a href="https://www.benzinga.com/news/earnings/23/02/30713474/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-january-where-do-spy-tesla-apple-and-ford">January</a>/<a href="https://www.benzinga.com/markets/penny-stocks/23/03/31137326/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-february-including-tesla-apple-and">February</a>/<a href="https://www.benzinga.com/markets/equities/24/04/38023764/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-march-where-do-tesla-nvidia-spy-and-re">March </a>Search Ranking: 3rd/1st/1st</li>
<li><a href="https://www.benzinga.com/exclusives/24/06/39234936/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-may-where-do-nvidia-tesla-gamestop-amc-ran">May</a>/<a href="https://www.benzinga.com/top-stories/24/07/39579249/exclusive-top-10-most-searched-tickers-on-benzinga-pro-in-june-where-do-nvidia-gamestop-tesla-apple">June</a>/<a href="https://www.benzinga.com/top-stories/24/08/40119459/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-july-2024-where-do-tesla-nvidia-apple-crow">July </a>Search Ranking: 2nd/1st/2nd</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $563.68</li>
<li>52-Week Range: $409.22 to $565.22</li>
<li>Year-to-Date Return: +19.3%</li>
<li>January/February/March Search Ranking: 2nd/2nd/3rd</li>
<li>May/June/July Search Ranking: 1st/3rd/3rd</li>
</ul>
3. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $214.11</li>
<li>52-Week Range: $138.80 to $278.97</li>
<li>Year-to-Date Return: -13.8%</li>
<li>January/February/March Search Ranking: 1st/4th/2nd</li>
<li>May/June/July Search Ranking: 4th/4th/1st</li>
</ul>
4. Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $437.70</li>
<li>52-Week Range: $226.59 to $1,229.00</li>
<li>Year-to-Date Return: +53.3%</li>
<li>January/February/March Search Ranking: Not in Top 20/Not in Top 20/5th</li>
<li>May/June/July Search Ranking: 14th/10th/19th</li>
</ul>
5. Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)
<ul>
<li>Current Price: $5.25</li>
<li>52-Week Range: $0.78 to $7.83</li>
<li>Year-to-Date Return: +17.8%</li>
<li>January/February/March Search Ranking: Not in Top 20</li>
<li>May/June/July Search Ranking: Not in Top 20</li>
</ul>
6. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $229.00</li>
<li>52-Week Range: $164.08 to $237.23</li>
<li>Year-to-Date Return: +23.4%</li>
<li>January/February/March Search Ranking: 5th/8th/4th</li>
<li>May/June/July Search Ranking: 6th/5th/7th</li>
</ul>
7. Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)
<ul>
<li>Current Price: $31.48</li>
<li>52-Week Range: $13.68 to $33.12</li>
<li>Year-to-Date Return: +89.9%</li>
<li>January/February/March Search Ranking: Not in Top 20/Not in Top 20/11th</li>
<li>May/June/July Search Ranking: 6th/5th/7th</li>
</ul>
8. Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)
<ul>
<li>Current Price: $148.56</li>
<li>52-Week Range: $93.12 to $227.30</li>
<li>Year-to-Date Return: +7.2%</li>
<li>January/February/March Search Ranking: 12th/14th/8th</li>
<li>May/June/July Search Ranking: 8th/9th/4th</li>
</ul>
9. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>Current Price: $476.27</li>
<li>52-Week Range: $342.35 to $503.52</li>
<li>Year-to-Date Return: +18.3%</li>
<li>January/February/March Search Ranking: 18th/Not in Top 20/9th</li>
<li>May/June/July Search Ranking: 9th/11th/11th</li>
</ul>
10. GeoVax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>)
<ul>
<li>Current Price: $4.63</li>
<li>52-Week Range: $1.09 to $11.18</li>
<li>Year-to-Date Return: -16.6%</li>
<li>January/February/March Search Ranking: Not in Top 20</li>
<li>May/June/July Search Ranking: Not in Top 20</li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent090324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090324&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in the first half of 2024:
11. Indonesia Energy Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INDO#AMEX">INDO</a>)
12. Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>)
13. Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
14. Cingulate Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>)
15. Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
16. Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)
17. Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>)
18. AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)
19. CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>)
20. Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>)
Why It's Important: Nvidia was the top searched stock on Benzinga Pro for the month of August thanks to<a href="https://www.benzinga.com/news/earnings/24/08/40613050/nvidia-q2-earnings-guidance-top-street-view-as-ai-fuels-record-data-center-revenue-gross-margin-fal"> its quarterly earnings </a>falling during the calendar month. The company beat estimates from analysts and shared guidance that was ahead of estimates. The stock has consistently ranked as one of the top three most-searched tickers on Benzinga Pro in each month this year. 
Tesla, which topped the month of July, fell to third place for the month of August. The electric vehicle stock has ranked among the four most-searched tickers each month during 2024.
Two ETFs were among the most-searched tickers in August, with SPY ranking second and QQQ ranking ninth. The SPY, which tracks the S&amp;P 500, regularly ranks as one of the top three most searched tickers each month. The QQQ, which tracks the Nasdaq 100, saw a boost in August, re-joining the top 10 for the first time since May.
Super Micro Computer saw a surge in interest in August, likely boosted<a href="https://www.benzinga.com/trading-ideas/short-ideas/24/08/40579899/super-micro-computer-stock-falls-on-short-report-hindenburg-says-company-has-accounting"> by a short report </a>and an update from the company. The stock previously ranked as high as fifth in March before the fourth-place ranking in August. The stock moved back into the top 10 for the first time since June's 10th place ranking.
Two newcomers joined the top 10 most searched tickers list, with Lumen Technologies ranking fifth and GeoVax Labs ranking 10th. Lumen <a href="https://www.benzinga.com/news/24/08/40221474/lumen-technologies-stock-continues-to-soar-whats-going-on">reported quarterly financial results</a> during the month and saw shares soar and gain interest from investors. GeoVax Labs saw high volatility and increased interest related to the<a href="https://www.benzinga.com/general/health-care/24/08/40381585/who-declares-mpox-public-health-emergency-coordinated-international-response-essential-to-hal"> emergency health declaration </a>by the World Health Organization on mpox. GeoVax Labs has vaccines that are said to be effective against mpox.
Falling out of the top 10 were Serve Robotics, which ranked 16th in August and Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>), which did not rank in the top 20 for August.
The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) continues to see strong interest from readers. The ETF, which tracks small cap stocks, ranked 24th in August following a 22nd ranking in July. With a potential Federal Reserve rate cut on the horizon, small cap stocks and ETFs could see increased interest in September.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/exclusives/24/08/40653930/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
Photo created using artificial intelligence via MidJourney.

Macro Notification

BWVI

iShares MSCI Israel Capped Investable Market Index Fund

WHO Chief Tedros Says Mpox Vaccines Could Be Ready For Emergency Use Listing Within Two Weeks; Some Mpox Vaccines Expected To Arrive In Congo In The Next Few Days

WHO Chief Tedros Says Received First Expression Of Interest For Emergency Use Listing From Mpox Diagnostics Manufacturer; WHO Officials Discuss Polio Vaccination Plan In Gaza, Confirm Applications From Bavarian Nordic And KM Biologics For Mpox Vaccines Emergency Use Listing, And Announce 230,000 Doses Available For Congo

CDC Says Clade I Mpox Outbreak Originating In Central Africa; Risk Of Mpox Coming Into U.S. Is Low; No Cases Of Clade I Mpox Have Been Reported In The U.S. At This Time; Best Protection Against Mpox Is Two Doses Of Jynneos Vaccine If Eligible; Working With Other U.S. Government Agencies & Partners On Strategy For Vaccination In Democratic Republic Of Congo

Bavarian Nordic rebounds as new mpox vaccine order boosts outlook

Mpox stocks in focus as Thailand reports first case in Asia linked to new strain

Tonix stock jumps on collaboration for mpox vaccine candidate

Labcorp considering ramping up mpox testing capacity: report

Trinity stock soars post-market on raised guidance, increased capacity

UNICEF issues emergency tender to secure mpox vaccines

Bavarian Nordic stock slides on Moderna mpox vaccine study

Applied DNA stock jumps amid U.S. government mpox update

Morocco reports first mpox case amid ongoing global outbreak

Applied DNA Sciences regains Nasdaq compliance

APNHF

BVNKF

BVNRY

CODX

RHHBF

RHHBY

SIGA

TRIB

Press Releases

CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit

Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

Earnings

Applied DNA Announces Third Quarter Fiscal Year 2024  Financial Results

Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I

Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan

Applied DNA Launches Mpox Clade I and Clade II  Testing Service

Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit

Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Applied DNA Sciences

Applied DNA Sciences (APDN) Forecast

Applied DNA Sciences (NASDAQ:APDN) Stock, Quote.Headers.trade-ideas